Table 8Studies included in KQ 1 network meta-analyses

Treatment ComparisonStudy NameACR50a bRadiographic Joint Damagea
ABA + MTX vs. MTXAGREE, 2009,31 2011,129, 130 2015131XX
ABA + MTX vs. ABA vs. MTXAVERT, 20157X
ADA + MTX vs. ADA vs. MTXPREMIER, 2006,15 2008,103 2010,115 2012,116 2013,117 2014,118 2015119XX
ADA + MTX vs. MTXPROWD, 2008,16 2016152 cX
CZP + MTX vs. MTXC-EARLY, 201738, 39XX
CZP + MTX vs. MTXC-OPERA, 2016,13 2017153 cXX
ETN vs. MTXEnbrel ERA, 2000,14 2002,110 2005,164 2006111XX
ETN + MTX vs. MTXCOMET, 2008,12 2009,154 2010,108, 109 2012;155 2014,156XX
IFX + MTX vs. MTXASPIRE, 2004,17 2006,107 2009,106 2017157XX
IFX + MTX vs. methyl-PNL + MTX vs. MTXDurez et al., 200718X
IFX + MTX vs. MTXQuinn et al., 200541X
SSZ + MTX vs. SSZ vs. MTXDougados et al., 1999;21 Maillefert et al., 2003104X
TCZ + MTX vs. TCZ vs. MTXFUNCTION, 2016,32 2017134XX
TCZ + MTX vs. TCZ vs. MTXU-Act-Early, 201633XX
a

All data used in NWMA were measured at the 1-year followup time point.

b

NWMA of DAS remission are presented in Appendix H.

c

Outcomes from these studies at the 1-year followup time point were rated as high ROB, and we therefore only used their data in sensitivity analyses presented in Appendix 1.

ABA = abatacept; ACR50 = American College of Rheumatology 50% improvement; ADA = adalimumab; CZP = certolizumab pegol; DAS = Disease Activity Score; ETN = etanercept; IFX = infliximab; KQ = Key Question; methyl-PNL = methylprednisolone; MTX = methotrexate; NA = not applicable; NWMA = network meta-analysis; PROWD = PRevention of Work Disability trial; ROB = risk of bias; SSZ = sulfasalazine; TCZ = tocilizumab; vs. = versus.

From: Results

Cover of Drug Therapy for Early Rheumatoid Arthritis: A Systematic Review Update
Drug Therapy for Early Rheumatoid Arthritis: A Systematic Review Update [Internet].
Comparative Effectiveness Review, No. 211.
Donahue KE, Gartlehner G, Schulman ER, et al.
Copyright Notice

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.